Activity of the nigro-striatal dopaminergic system during precipitated morphine withdrawal investigated in rats with acute unilateral inactivation of the striatum.
The activity of the striatal dopamine system during precipitated morphine withdrawl was studied in rats using a model in which the striatum was unilaterally inactivated by the local injection of KCl. In naive rats dopamine agonists administered just prior to KCL induced ipsilateral turning or circling, while dopamine antagonists in the same situation caused contralateral turning. Withdrawal precipitated by morphine antagonists in rats made dependent by repeated implantation of morphine pellets induced contralateral circling during unilateral inactivation of the striatum. This contralateral circling was only slightly enhanced by haloperidol, but strongly enhanced by a low dosage of apomorphine as well as by some weak dopamine agonists such as CB 154 or By 101. However, high doses of apomorphine completely reversed the withdrawal-induced contralateral circling into ipsilateral circling. Other dopamine agonists, such as d-amphetamine, L-Dopa and piribedil, did not abolish the withdrawal-induced contralateral circling, however, they caused the appearance of an additional ipsilateral circling. Other types of drugs which are known to intensify withdrawal-induced jumping (desipramine, atropine, caffeine) enhanced contralateral circling. There are also other parallels jumping and contralateral circling induced by withdrawal. The direction of naloxone-induced asymmetric behaviour during acute unilateral inactivation of the striatum suggests that striatal dopaminergic activity is reduced during precipitated withdrawal; the other results reported point to the possiblity that extrastriatal dopaminergic mechanisms or different dopamine receptor types within the striatum are involved.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D003342:Corpus Striatum / Q000503:physiopathology*; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D006801:Humans; D007267:Injections; D008297:Male; D009021:Morphine Dependence / Q000503:physiopathology*; D011189:Potassium Chloride / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D012399:Rotation; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D013378:Substantia Nigra / Q000503:physiopathology*
D018492:Dopamine Antagonists; D011189:Potassium Chloride; D004298:Dopamine